Drug Trial Radar · NCT03876262
Safety and Efficacy of Annual or Biannual Doses of Moxidectin or Ivermectin for Onchocerciasis
Last checked: Nov 19, 2026Latest source record: Dec 23, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
323
Actual
Start
May 3, 2021
Primary completion
Jul 31, 2024
Study completion Jan 1, 2026
Sponsor
- Lead sponsor
- Medicines Development for Global HealthAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Mar 15, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose of this phase 3b study is to determine the safety and efficacy of moxidectin administration twice a year, compared to once a year, in maintaining undetectable levels in skin of O. volvulus microfilaria in skin, the parasite that causes river blindness. Secondary purposes are to determine the effectiveness of moxidectin compared to ivermectin once or twice a year in maintaining undetectable levels, or reducing levels, of skin microfilaria.
Conditions
- Onchocerciasis
Interventions
MoxidectinDrug
2mg tablets, encapsulated for blinding
IvermectinDrug
3mg tablets, encapsulated for blinding
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of moxidectin annual and biannual recipients with sustained microfilarial response at month 12Time frame: Up to 12 months
- Incidence and severity of adverse eventsTime frame: Up to 36 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Centre de Recherche pour les Maladies Tropicales Negligees
Rethy, Ituri, Democratic Republic of the Congo
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.